Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
According to a story from globenewswire.com, the biopharmaceutical company Marinus Pharmaceuticals, Inc., recently announced the presentation of Phase 2 clinical trial of the drug ganaxolone as a treatment for CDKL5…